DISCOVER

Our News

June 2022, 22 - Breakthrough Status allows for enhanced interaction with FDA and recognizes SonoCloud® as innovative and promising approach for treatment of recurrent glioblastoma.

June 9, 2021 - SonoCloud® device can enhance delivery of CAR-T therapies and penetration of checkpoint inhibitors into the brain of preclinical glioma models.

December 16, 2020 - The trial will recruit up to 39 patients with recurrent glioblastoma to test the SonoCloud-9 device in combination with Abraxane®.

September 14, 2020 - Carthera announces that it has been selected by the EIC (European Innovation Council) pilot gas pedal program for the development of its DOMEUS project.

June 8,2020 - The SoniMel study aims to demonstrate safety of using the SonoCloud® technology with checkpoint inhibitors for the treatment of brain metastases from melanoma.

December 9, 2019 - Carthera enters into a strategic collaboration agreement with U.S.-based Lantheus to provide microbubbles for use with the SonoCloud device.

Carthera will present at this conference an update on its on-going work to develop the SonoCloud for treatment of brain tumors.

November 18, 2019 - KIYATEC and Carthera announce that they have entered into a clinical collaboration for the purpose of advancing innovation and improving treatments for patients with glioblastoma.

July 9, 2019 - Carthera receives FDA approval to launch a Phase 1/2a clinical trial in the US with its SonoCloud-9 device in patients with recurrent glioblastoma.

June 25, 2019 - Carthera appoints Pascal Girin as chairman of Board of Directors